Hi dleb,
Interesting night ahead, Biota recieved $32.3m last quarter and this was before swine flu hit so it has to be greater than that amount one would think.
The forward sales will be worth watching given Tamiflu's poor performance.
If they announce that a simpler device for administering Relenza is approved then they will be able to ramp up the production to the 160m as the disk inhaler is the bottleneck in Relenza production.
